Subscribe
shutterstock_1608843100_ron_adar-1
Ron Adar / Shutterstock.com
15 April 2021AmericasAlex Baldwin

Former world leaders call on Biden to waive COVID IPs

A group of more than 170 former world leaders and Nobel Laureates has called upon US President Joe Biden to waive IP rights for COVID vaccines, in an open letter posted yesterday.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
Senator calls on Biden to reject COVID IP waiver
2 March 2021   Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation.
Generics
POTUS orders crackdown on anticompetitive drug practices
13 July 2021   An executive order by President Joe Biden has targeted anti-competitive practices in the US drugs market, including a ban of pay-for-delay agreements.
Biotechnology
Activists urge Biden to champion temporary COVID-19 IP waiver
23 November 2021   Medical and human rights groups have called on US President Joe Biden to step up his personal engagement and help put in place a temporary waiver of IP rights for COVID-19 vaccines.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Medtech
Senator calls on Biden to reject COVID IP waiver
2 March 2021   Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation.
Generics
POTUS orders crackdown on anticompetitive drug practices
13 July 2021   An executive order by President Joe Biden has targeted anti-competitive practices in the US drugs market, including a ban of pay-for-delay agreements.
Biotechnology
Activists urge Biden to champion temporary COVID-19 IP waiver
23 November 2021   Medical and human rights groups have called on US President Joe Biden to step up his personal engagement and help put in place a temporary waiver of IP rights for COVID-19 vaccines.

More on this story

Medtech
Senator calls on Biden to reject COVID IP waiver
2 March 2021   Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation.
Generics
POTUS orders crackdown on anticompetitive drug practices
13 July 2021   An executive order by President Joe Biden has targeted anti-competitive practices in the US drugs market, including a ban of pay-for-delay agreements.
Biotechnology
Activists urge Biden to champion temporary COVID-19 IP waiver
23 November 2021   Medical and human rights groups have called on US President Joe Biden to step up his personal engagement and help put in place a temporary waiver of IP rights for COVID-19 vaccines.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York